| Document |
Document Title |
|
WO/2005/068415A1 |
Disclosed is a phenylalanine derivative having excellent VLA-4 inhibitory activity which is represented by the following general formula (1) or a salt thereof. (1) (In the formula, R1 represents an aromatic hydrocarbon group having 6-10 ...
|
|
WO/2005/065779A1 |
The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors ('CGRP-receptor'), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment usin...
|
|
WO/2005/063222A1 |
An Hsp90 family protein inhibitor which contains as an active ingredient a benzene derivative represented by the following general formula (I), a prodrug thereof, or a pharmacologically acceptable salt of either.
|
|
WO/2005/062811A2 |
One aspect of the present invention relates to a method of preparing allylic carboxylate compounds comprising the step of contacting a compound comprising an allylic hydrogen atom with a carboxylic acid in the presence of palladium, a su...
|
|
WO/2005/061482A1 |
Methods, compositions and kits are disclosed. Enzyme conjugates of Formula (I) are employed in assays for the determination of an methylenedioxyamphetamine, a methylene-dioxyethamphetamine, and/or a methylenedioxymethamphetamine. Immunog...
|
|
WO/2005/061443A2 |
The invention relates to benzoyl-substituted phenylalanine amides of formula (I), wherein the variables R1 to R15 have the meanings indicated in the description, the agriculturally useful salts thereof, methods and intermediate products ...
|
|
WO/2005/060692A2 |
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.
|
|
WO/2005/058865A2 |
Methods, compositions and kits are disclosed. The methods are directed to determining the presence of entactogen analytes such as, for example, 3,4-methylenedioxamphetamine (MDA), 3,4-methylenedioxy-methamphetamine (MDMA), 3,4-methylened...
|
|
WO/2005/058863A1 |
Disclosed are reactive cyclic carbonates and ureas of formula (I) or (II), wherein R and X have the meaning indicated in the description. Said carbonates and ureas allow functional groups to be specifically introduced into biomolecules, ...
|
|
WO/2005/058832A1 |
The present invention relates to diacylhydrazine derivatives of formula I, the use of the compounds of formula I as inhibitors of raf-kinase, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a...
|
|
WO/2005/058864A1 |
Methods, compositions and kits are disclosed. The methods are directed to determining the presence of entactogen analytes such as, for example, 3,4methylenedioxyamphetamine (MDA)3,4-methylenedioxy-methamphetamine (MDMA), 3,4-methylened...
|
|
WO/2005/055941A2 |
Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.
|
|
WO/2005/054429A2 |
The present invention relates to alternative methods for producing keto-acid synthons, which are useful for the synthesis of epothilones and analogs and derivatives thereof. A general method according to the present invention broadly com...
|
|
WO/2005/054313A1 |
A fluorinated polymer comprising an unit represented by the following formula (1), a methods for producing fluorinated compounds and the fluorinated polymers, and an optical/electrical material or coating material comprising the fluorina...
|
|
WO/2005/053610A2 |
The present invention relates to a novel class of hydroxamic acid derivatives having a diamine or iminodiacetic acid backbone. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit hist...
|
|
WO/2005/051373A1 |
A 14273 receptor function regulating agent useful as a preventive/therapeutic agent for diabetes, hyperlipemia, etc. There is provided a 14273 receptor function regulating agent comprising a compound having a group capable of releasing a...
|
|
WO/2005/051939A1 |
A process comprising contacting a propylene oxide feed with carbon dioxide in the presence of a suitable catalyst to obtain a reaction mixture comprising propylene carbonate in which process the propylene oxide feed comprises at least 50...
|
|
WO/2005/049604A2 |
This application relates to a compound of formula I (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of fa...
|
|
WO/2005/049023A1 |
The invention provides a compound of formula (I): or a salt, solvate or a physiologically functional derivative thereof, wherein R1 to R10 are as defined in the specification and uses of such compounds. The compounds inhibit GlyT1 transp...
|
|
WO/2005/046683A1 |
Compounds are disclosed that have a formula represented by the following: Formula (I) The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals in...
|
|
WO2005015158A9 |
The invention relates to compounds that specifically bind a T1R1/T1R3 or T1R2/T1R3 receptor or fragments or subunits thereof. The present invention also relates to the use of hetero-oligomeric and chimeric taste receptors comprising T1R1...
|
|
WO/2005/044790A1 |
The invention relates to a method for producing cyclohexene derivatives of the general formulae (I) or (II), in which the substituents R1 and R2 independently of one another are defined as follows: R1 = (formula A, B, C, or D); R2 repres...
|
|
WO/2005/044007A1 |
A pesticide having stabilized high pesticidal effects for crop plants infected with plant diseases, is presented. The pesticide contains a biphenyl derivative represented by the formula (I) or its salt, as an active ingredient: wherein X...
|
|
WO/2005/042512A1 |
A new high-yield, easily industrialized process for synthesising compounds of formula (IV), in which X1 and X2, the same or different, are linear or branched C1-C8 alkyls, n and m are 0,1 or 2, with the proviso that n and m are not simul...
|
|
WO/2005/041684A2 |
The present invention relates to the discovery that certain non-naturally occurring, non-peptide arride compounds and amide derivatives, such as oxalamides, ureas, and acrylamides, are useful flavor or taste modifiers, such as a flavorin...
|
|
WO/2005/042511A1 |
A fluoropolymer which is excellent in mechanical strength and transparency, has a high glass transition temperature which makes the polymer suitable for high-temperature use, and has a high refractive index. Also provided is a novel comp...
|
|
WO/2005/040100A1 |
This invention relates to tetrahydro-naphthalene and urea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The tetrahydro-naphthalene and urea derivatives of the present invention have ...
|
|
WO/2005/040149A1 |
The invention relates to a process for the preparation of glyceraldehyde acetonide by oxidation of 2,2-dimethyl-1,3-dioxolane-4-methanol by an oxidizing agent, wherein the 2,2-dimethyl-1,3-dioxolane-4-methanol is oxidized by an organic N...
|
|
WO/2005/040148A1 |
The present invention relates to a new compound of the following formula (I).
|
|
WO/2005/040109A1 |
Compounds which function as melanocortin receptor ligands and having utility in the treatment of melanocortin receptor-based disorders. The compounds have the following structure (I): (R4)s (R 2)n N˜ X1-X2 (CR1aCRlb)q 1˜ N R1-lm 1 O R3...
|
|
WO/2005/037207A2 |
The present invention is directed to alkanoyl and cycloalkanoyl-amine derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake inclu...
|
|
WO/2005/037279A1 |
The present invention is directed to substituted N-heterocycle derivatives of formula (I), compositions containing these derivatives, and their use in the manufacture of a medicament for the prevention and treatment of conditions amelior...
|
|
WO/2005/037283A1 |
The present invention is directed to fused-aryl and heteroaryl derivatives of formula I, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake...
|
|
WO/2005/037819A1 |
The invention relates to a process for the preparation of (S)-glyceraldehyde acetonide in aqueous solution from 3,4-O-isopropylidene-L-threonic acid or a salt thereof in aqueous solution, and hypochlorite in aqueous solution wherein th...
|
|
WO/2005/037818A1 |
Disclosed are a novel fluorine-containing dioxolane compound which can be used as a raw material for a fluorine-containing polymer that is excellent in characteristics such as heat resistance, mechanical strength, transparency and rigidi...
|
|
WO/2005/037807A1 |
The present invention is directed to arylalkyl- and cycloalkylalkyl-piperazine derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reupt...
|
|
WO/2005/037809A1 |
The present invention is directed to substituted aryl cycloalkanoyl derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake includi...
|
|
WO/2005/034940A2 |
The invention relates to substances, which specifically inhibit both Ala-p-nitroanilide-cleaving peptidases as well as Gly-Pro-p-nitroanilide-cleaving peptidases, for use in the field of medicine. The invention also relates to the use of...
|
|
WO/2005/030694A1 |
The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.
|
|
WO/2005/026134A1 |
Compounds of the formula (I) provide pharmacological agents which bind to Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compounds of the present invention are useful for the treatment of conditions mediated by the...
|
|
WO/2005/026163A1 |
The present invention relates to dioxolane derivatives as cell adhesion inhibitors. These compounds can be useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies, including inflammatory and autoimmun...
|
|
WO/2005/027157A2 |
A salt fusible at ordinary temperature which comprises: a cation ingredient obtained by introducing a cationic group into a volatile organic solvent; and an anion ingredient selected from the group consisting of an inorganic ion, sulfoni...
|
|
WO/2005/023242A1 |
The present invention relates to small molecules as entry inhibitors of the HIV virus, processes for their preparation as well as pharmaceutical compositions, their use as medicines, and diagnostic kits comprising them. The present inven...
|
|
WO/2005/021526A2 |
A production method of fluorinated compounds, for producing a compound represented by formula (3) in a fluorine-based solution in a flow of fluorine gas after reaction of at least one type of compounds represented by formula (1) and at l...
|
|
WO/2005/021523A1 |
New piperazine substituted compounds of formula (1) have been found to be useful in treatinf conditions associated with calcium channel function. These piperazine derivatives are useful in treating conditions such as stroke, pain, anxiet...
|
|
WO/2005/020897A2 |
Provided are small-molecule Trp-p8 modulators, including Trp-p8 agonists and Trp-p8 antagonists, and compositions comprising small-molecule Trp-p8 agonists as well as methods for identifying and characterizing novel small-molecule Trp-p8...
|
|
WO/2005/020911A2 |
The present invention relates to benzo[1, 3]dioxole compounds and pharmaceutical compositions containing such compounds. These compounds and compositions may be made by various methods. These compounds and compositions may be used to tre...
|
|
WO/2005/019194A1 |
Compounds of formula (I) are inhibitors of matrix metalloproteinases, and are of use in the treatment of, for example fibrotic disease, multiple sclerosis, emphysemia, bronchitis and asthma: formula (I) wherein Ar represents an optionall...
|
|
WO/2005/019159A1 |
A process for producing corresponding &agr -aminooxyketones in high yield and with high enantioselectivity, that is, a process for the production of optically active &agr -aminooxyketone derivatives represented by the general formula (1)...
|
|
WO/2005/019192A1 |
The invention relates to novel urea derivatives which inhibit tyrosinkinases, especially TIE-2, and Raf kinases and which are used in the treatment of tumors.
|
